• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

BlueCross BlueShield of Tennessee to Cover COVID-19 Booster


The plan will cover administration of the booster for those with cancer or who are immunocompromised.

BlueCross BlueShield of Tennessee will cover the administration cost for a COVID-19 booster for those who are moderately to severely immunocompromised, including those undergoing cancer treatment. Organization executives said in a statement that members in commercial Blue Network S, P and L, as well as Medicare Advantage, BlueCare Tennessee and BlueCare Plus Tennessee will also be able to get a booster without any out-of-pocket costs.

Andrea Willis, M.D.

Andrea Willis, M.D.

“It’s our responsibility to support members seeking to protect themselves against COVID-19. Research has demonstrated the clear value of a booster to reduce risk, which ultimately will help communities facing the Delta variant surge,” Andrea Willis, M.D., chief medical officer for BlueCross.

The Centers for Disease Control recommends COVID-19 vaccine boosters for those who:

  • Are receiving active cancer treatment for tumors or cancers of the blood
  • Received an organ transplant and are taking medicine to suppress the immune system
  • Received a stem cell transplant within the last 2 years or are taking medicine to suppress the immune system
  • Have a moderate or severe primary immunodeficiency
  • Have an advanced or untreated HIV infection
  • Are undergoing active treatment with high-dose corticosteroids or other drugs that may suppress their immune response

Additional, the plan is waiving member costs for medically necessary COVID-19 testing until the end of the national public health emergency, and last year made permanent coverage for in-network telehealth visits for members with employer-based or individual plans.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.